DRMA
Dermata Therapeutics, Inc. NASDAQ$1.30
Mkt Cap $886,024
52w Low $1.10
2.3% of range
52w High $9.90
50d MA $1.28
200d MA $3.24
P/E (TTM)
-0.2x
EV/EBITDA
967.4x
P/B
0.0x
Debt/Equity
0.0x
ROE
-121.4%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$1.28
200d MA
$3.24
Avg Volume
1.5M
About
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for M…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -1.54 | -1.52 | +1.3% | 1.37 | -0.7% | -13.9% | -16.8% | -11.7% | -12.4% | -5.8% | — |
| Nov 14, 2025 | AMC | -1.59 | -1.65 | -3.8% | 3.07 | +2.0% | -7.5% | -13.0% | -20.5% | -18.6% | -15.3% | — |
| Aug 13, 2025 | AMC | -2.90 | -1.66 | +42.8% | 6.45 | -1.4% | -9.9% | -7.3% | -8.2% | -12.6% | -16.1% | — |
| May 14, 2025 | AMC | -0.45 | -4.50 | -900.0% | 0.78 | -2.4% | +1.9% | +1.5% | +6.5% | +3.7% | -1.1% | — |
| Mar 17, 2025 | AMC | -1.50 | -3.15 | -110.0% | 1.17 | +0.0% | +2.6% | +4.3% | +0.9% | +6.0% | +11.1% | — |
| Nov 13, 2024 | AMC | -2.64 | -2.04 | +22.7% | 1.23 | +0.0% | -3.3% | -8.9% | -12.2% | -12.2% | -5.7% | — |
| Aug 7, 2024 | AMC | -3.79 | -4.18 | -10.3% | 2.33 | -7.7% | +12.4% | +5.6% | -2.6% | -5.2% | -3.0% | — |
| May 15, 2024 | AMC | -5.40 | -7.05 | -30.6% | 4.95 | -2.0% | +5.1% | -15.2% | -24.0% | -30.9% | -26.9% | — |
| Mar 21, 2024 | AMC | -0.78 | -3.15 | -303.8% | 6.00 | +8.8% | +3.8% | +3.8% | +1.0% | -1.7% | +2.7% | — |
| Nov 9, 2023 | AMC | -0.63 | -8.10 | -1185.7% | 11.73 | -4.9% | -7.8% | -14.3% | -17.8% | -16.6% | -11.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21 | Maxim Group | Maintains | Buy → Buy | — | $5.41 | $5.24 | -3.1% | -1.5% | +1.3% | +7.8% | +1.7% | -2.2% |
| May 21 | Maxim Group | Maintains | Buy → Buy | — | $0.81 | $0.82 | +1.5% | -4.7% | -4.9% | -7.9% | -7.2% | -9.6% |
| Aug 21 | Maxim Group | Maintains | Buy → Buy | — | $2.02 | $2.03 | +0.5% | -4.0% | -8.9% | -11.4% | -16.3% | -13.4% |
| Mar 23 | Maxim Group | Maintains | Buy → Buy | — | $20.10 | $20.85 | +3.7% | +25.4% | +14.9% | +3.7% | -6.7% | +0.7% |
Recent Filings
8-K
Unknown — 8-K Filing
Dermata reported 2025 year-end results via 8-K filing, signaling material corporate developments that investors should monitor for revenue trends, profitability changes, and strategic direction affecting stock valuation.
Mar 26
8-K · 5.02
!!! Very High
Dermata Therapeutics, Inc. -- 8-K 5.02: Executive Change
Dermata Therapeutics loses director Mary Fisher on March 31, 2026, representing a board-level departure that investors should monitor for potential strategic implications.
Feb 25
8-K · 4.01
!!! Very High
Dermata Therapeutics, Inc. -- 8-K 4.01: Auditor Change / Resignation
Dermata Therapeutics dismissed its independent auditor, a routine corporate housekeeping change that typically signals either cost management or dissatisfaction with audit quality and services.
Feb 3
Data updated apr 25, 2026 5:46am
· Source: massive.com